Jyoti

Jyoti Therapeutics is a private, stealth-mode biotechnology company focused on the discovery and development of novel oncology treatments at the intersection of the human microbiome and cancer biology. The company leverages a proprietary platform to identify microbial-derived targets within the tumor microenvironment that can be exploited to enhance anti-tumor immune responses. Backed by top-tier investors including SR One, GV, and Casdin Capital, Jyoti aims to address the limitations of current immunotherapies by targeting unique pathways influenced by the microbiome. The company is headquartered in South San Francisco and is currently advancing its programs through the pre-clinical stage. Its research represents a frontier in immuno-oncology, seeking to translate complex microbial interactions into transformative therapies for patients with solid tumors.